<DOC>
	<DOCNO>NCT00070304</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine vinorelbine , use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : This phase II trial study well give gemcitabine together vinorelbine work treat young patient recurrent refractory Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Gemcitabine Vinorelbine Treating Young Patients With Recurrent Refractory Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate pediatric patient recurrent refractory Hodgkin 's lymphoma treat gemcitabine vinorelbine . - Determine toxicity regimen patient . OUTLINE : This nonrandomized , multicenter study . Patients receive vinorelbine IV 6-10 minute gemcitabine IV 100 minute day 1 8 . Patients also receive filgrastim ( G-CSF ) subcutaneously daily begin day 9 continue least 7 day blood count recover . Treatment repeat every 21 day least 2 course absence disease progression unacceptable toxicity . Patients respond disease 2 course may proceed directly stem cell transplantation study OR receive 2 additional course . Patients stable disease 2 course receive least 2 additional course . Patients continue stable respond disease ( disease progression ) 4 course may continue receive study treatment 1 year discontinue study alternative therapy discretion treat physician . Patients follow survival . PROJECTED ACCRUAL : A total 13-26 patient accrue study within 1.5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm Hodgkin 's lymphoma* follow histology : Not otherwise specify ( NOS ) Mixed cellularity NOS Lymphocytic depletion NOS Diffuse fibrosis Reticular Lymphocytic predominance NOS Diffuse Nodular Paragranuloma Granuloma Sarcoma Nodular sclerosis Cellular phase NOS Lymphocytic predominance Mixed cellularity Lymphocytic depletion NOTE : *Disease metastatic bone marrow granulocytopenia and/or thrombocytopenia allow , evaluable hematological toxicity Measurable disease clinical radiographic criterion Relapsed refractory conventional therapy Received least 2 prior cytotoxic chemotherapy regimens No stage IA IIA nodal disease previously treat follow : Radiotherapy No 4 course prior chemotherapy PATIENT CHARACTERISTICS : Age 30 Performance status Karnofsky 50100 % ( 16 year age ) Lansky 50100 % ( 16 ) OR ECOG 02 Life expectancy At least 8 week Hematopoietic See Disease Characteristics Absolute neutrophil count ≥ 750/mm^3 Platelet count ≥ 75,000/mm^3 ( transfusion independent , define ≥ 3 day since prior platelet transfusion ) Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT ≤ 2.5 time ULN Renal Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min OR Creatinine base age follow : No great 0.8 mg/dL ( age 5 ) No great 1.0 mg/dL ( age 6 10 ) No great 1.2 mg/dL ( age 11 15 ) No great 1.5 mg/dL ( age 15 ) Pulmonary DLCO ≥ 50 % FEV_1 ≥ 50 % Vital capacity ≥ 50 % No evidence dyspnea rest No exercise intolerance Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation Seizure disorder allow provided patient anticonvulsant disorder well control No evidence active graftversushost disease PRIOR CONCURRENT THERAPY : Biologic therapy Recovered prior immunotherapy At least 6 month since prior allogeneic stem cell transplantation ( SCT ) At least 7 day since prior biologic agent More 3 month since prior autologous SCT More 1 week since prior growth factor No concurrent immunomodulating agent Chemotherapy See Disease Characteristics More 2 week since prior myelosuppressive chemotherapy ( 4 week nitrosoureas ) recover No prior gemcitabine vinorelbine combination ( i.e. , administer within 1 week ) Prior gemcitabine vinorelbine administer alone allow No concurrent chemotherapy Endocrine therapy No concurrent steroid , include corticosteroid antiemetic control graftversushost disease Concurrent corticosteroid allow follow indication : Adrenal crisis patient suppress pituitary/adrenal response Noncardiogenic pulmonary edema Allergic reaction amphotericin transfusion treat lowdose hydrocortisone ( le 100 mg/m^2 ) Radiotherapy See Disease Characteristics At least 3 week since prior radiotherapy recover Surgery Not specify Other Concurrent immunosuppressive drug allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>childhood lymphocyte predominant Hodgkin lymphoma</keyword>
	<keyword>childhood lymphocyte depletion Hodgkin lymphoma</keyword>
	<keyword>childhood nodular sclerosis Hodgkin lymphoma</keyword>
	<keyword>childhood mixed cellularity Hodgkin lymphoma</keyword>
</DOC>